|
JP2017154980A
|
|
AGE-derived melanin production inhibitor and AGE-derived melanin production method
|
|
AU2008201790A1
|
|
Morinda Citrifolia-Based Formulation 5-Lox and 15-Lox
|
|
CN1946414A
|
|
Improving profiles of lipid proteins and inhibiting HMG-CoA reductase
|
|
EP1711193A2
|
|
IMPROVING PROFILES OF LIPID PROTEINS AND INHIBITING HMG-CoA REDUCTASE
|
|
CN1953764A
|
|
Type II diabetes
|
|
CN1859852A
|
|
Morinda citrifolia-based oral care compositions and methods
|
|
CN1863541A
|
|
Formulations and methods for treating breast cancer with morinda citrifolia and methylsulfonymethane
|
|
WO2005025410A2
|
|
Formulations and methods for treating breast cancer with morinda citrifolia and methylsulfonymethane
|
|
MXPA06001651A
|
|
Preventative effects of morinda citrifolia on mammary breast cancer.
|
|
CN101443027A
|
|
Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
|
|
WO2004098514A2
|
|
Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
|
|
JP2004331648A
|
|
Method and formulation for inhibiting naturally occurring phosphodiesterase
|
|
CN1849128A
|
|
Selectively inhibiting estrogen production and providing estrogenic effects in the human body
|
|
WO2004091545A2
|
|
Selectively inhibiting estrogen production and providing estrogenic effects in the human body
|
|
CN1711097A
|
|
Anti-angiogenesis effects of morinda citrifolia
|
|
JP2004359593A
|
|
Agricultural vitalizing agent containing extract of morinda citrifolia
|
|
US7048952B2
|
|
Formulation for inhibiting fungal and microbial growth comprising morinda citrifolia puree juice
|
|
US7014873B2
|
|
Method and formulation for treating candidiasis using morinda citrifolia
|
|
US6855345B2
|
|
Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions
|
|
US7070813B2
|
|
Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
|
